Reported 0 shares, down 244,151 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 6443000 |
| 2022-03-31 | 4111000 |
| 2022-06-30 | 5176000 |
| 2022-09-30 | 5027000 |
| 2022-12-31 | 2632000 |
| 2023-03-31 | 2783681 |
| 2023-06-30 | 558862 |
| 2023-09-30 | 310187 |
| 2023-12-31 | 546988 |
| 2024-03-31 | 649569 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -244,151 (-100.0%) | 0 | $0 | 2024-08-09 | |
| Q1 2024 | Added | 244,151 | +13,398 (5.8%) | < 0.01% | $649,569 | 2024-05-13 | |
| Q4 2023 | Added | 230,753 | +9,239 (4.2%) | < 0.01% | $546,988 | 2024-02-13 | |
| Q3 2023 | Added | 221,514 | +37,071 (20.1%) | < 0.01% | $310,187 | 2023-11-13 | |
| Q2 2023 | Reduced | 184,443 | -260,946 (-58.6%) | < 0.01% | $558,862 | 2023-08-11 | |
| Q1 2023 | Added | 445,389 | +13,775 (3.2%) | < 0.01% | $2,783,681 | 2023-05-15 | |
| Q4 2022 | Added | 431,614 | +10,905 (2.6%) | < 0.01% | $2,632,000 | 2023-02-13 | |
| Q3 2022 | Added | 420,709 | +10,225 (2.5%) | < 0.01% | $5,027,000 | 2022-11-14 | |
| Q2 2022 | Added | 410,484 | +45,381 (12.4%) | < 0.01% | $5,176,000 | 2022-08-12 | |
| Q1 2022 | Added | 365,103 | +1,471 (0.4%) | < 0.01% | $4,111,000 | 2022-05-13 | |
| Q4 2021 | Added | 363,632 | +26,410 (7.8%) | < 0.01% | $6,443,000 | 2022-02-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
57 managers reported KINNATE BIOPHARMA INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB publ | Reduced | 0 | -51,200 | 0 | $0 | 2 qtrs |
| DEUTSCHE BANK AG | Reduced | 0 | -114,846 | 0 | $0 | 14 qtrs |
| ROYAL BANK OF CANADA | Reduced | 0 | -14 | 0 | $0 | 15 qtrs |
| COWEN AND COMPANY LLC | Reduced | 0 | -25,000 | 0 | $0 | 2 qtrs |
| VANGUARD GROUP INC | Reduced | 0 | -1,076,789 | 0 | $0 | 15 qtrs |
| Tower Research Capital LLC TRC | Reduced | 0 | -1,091 | 0 | $0 | 14 qtrs |
| MORGAN STANLEY | Reduced | 0 | -7,427 | 0 | $0 | 13 qtrs |
| JANE STREET GROUP LLC | Reduced | 0 | -42,378 | 0 | $0 | 9 qtrs |
| RHUMBLINE ADVISERS | Reduced | 0 | -2,933 | 0 | $0 | 14 qtrs |
| XTX Topco Ltd | Reduced | 0 | -104,437 | 0 | $0 | 7 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- August 09, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.